NOVEL PLATFORM DEVELOPMENT
We don't just run assays. We build the ones that don't exist yet.
ADR Solutions is an R&D partner for pharmaceutical companies, academic researchers, and industry collaborators who need validated screening capability built from the ground up — for targets where no established assay currently exists.
WHAT THIS IS
R&D partnerships for targets that need a new approach
The antiparasitic drug discovery pipeline increasingly requires screening capability for targets outside the traditional catalog — ectoparasites, emerging nematode resistance mechanisms, species-specific models. Building validated assays for these targets takes deep parasitology expertise, access to live parasite material, and the research infrastructure to do it properly.
ADR Solutions works with partners to design, develop, and validate novel in vitro screening platforms — with milestone-based delivery structures suited to pharma and industry timelines.
This is not a catalog service. Every project is scoped individually. If you have a target and need a validated assay, we'd like to talk.
Pharma & biotech partners
Drug discovery programs that need validated screening infrastructure for antiparasitic targets where no established assay exists.
Academic researchers
Research groups studying novel parasite targets or resistance mechanisms who need assay development support and access to live parasite material.
Industry collaborators
Animal health companies and research organizations looking for a scientific partner to co-develop screening capability.
CURRENT DEVELOPMENT
Platforms in active development
These platforms are currently under development. If one of these is relevant to your program, we'd welcome a conversation
IN DEVELOPMENT
Ctenocephalides felis — adult flea assay
An in vitro motility assay for adult cat fleas — an ectoparasite target with significant commercial relevance in companion animal health for which validated screening platforms are limited. Tarsal and sensory assay formats in development.
IN DEVELOPMENT
Ancylostoma caninum — drug resistance assay
A targeted assay for detecting and characterizing anthelmintic resistance in canine hookworm — an emerging and serious concern in companion animal medicine with increasing relevance for drug efficacy research.
Don’t see your target?
We evaluate new platform development projects on a case-by-case basis. If you have a target that needs a validated assay, reach out — we're interested in understanding the problem before committing to whether we can solve it.
HOW WE WORK TOGETHER
What a collaboration looks like
1
Discovery conversation
We discuss your target, your program needs, and what a validated assay would need to deliver. No commitment required at this stage.
Scoping & proposal
We develop a technical proposal with defined milestones, deliverables, and timeline. IP arrangements discussed at this stage.
Development & validation
We build and validate the platform with regular milestone check-ins. All work performed under confidentiality agreement.
Delivery & handoff
Validated platform delivered with full documentation. Ongoing screening services available once the platform is established.
2
3
4
In vivo study support
In vivo parasite study support is available for partners with appropriate needs. Contact us directly to discuss.
Have a target that needs a new assay?
We're interested in the problem before we commit to the solution. Let's start with a conversation.